Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation

Abstract

The aim of the present study was to examine the effects of suppression of EphB4 and/or mTOR on the biological behaviors of ovarian cancer cells, and the potential regulatory pathways. Antisense EphB4 vectors and shRNA vectors targeting mammalian target of rapamycin (mTOR) were constructed and transfected into A2780 and SKOV3 cells (two ovarian cancer cell lines). The effects of the antisense EphB4 vectors and the shRNA vectors on the proliferation, apoptosis and invasion of ovarian cancer cells were measured, and the expression of EphB4, mTOR and Akt detected. The results showed that transfection with mTOR shRNA could inhibit growth, induce apoptosis, and reduce invasive ability of ovarian cancer cells, which was accompanied by downregulation of EphB4, mTOR and Akt. The inhibitory effects on cell growth caused by mTOR shRNA alone were weaker than those by antisense pEGFP-C1-EphB4. In the antisense pEGFP-C1-EphB4-transfected cells, it was found that EphB4 knockdown could decrease the mTOR expression and slightly reduce the Akt phosphorylation. Significant suppressive effects on cell growth were observed in cells co-transfected with antisense pEGFP-C1-EphB4 and mTOR shRNA. In co-transfection group, the expression levels of EphB4, mTOR and Akt were distinctly lower than those in other groups. It was concluded that suppression of EphB4 may inhibit the growth of ovarian cancer cells by downregulation of the PI3K/Akt/mTOR pathway, and reverse Akt phosphorylation induced by mTOR shRNA. Inhibition of EphB4 and mTOR combined may cooperatively suppress the biological behaviors of ovarian cancer cells.

Keywords

ovarian cancer / EphB4 / mTOR / Akt / apoptosis

References

[1] FooS.S., TurnerC.J., AdamsS., et al.. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell, 2006, 124(1): 161-173

[2] ScehnetJ.S., LeyE.J., KrasnoperovV., et al.. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood, 2009, 113(1): 254-263

[3] NorenN.K., LuM., FreemanA.L., et al.. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA, 2004, 101(15): 5583-5588

[4] AlamS.M., FujimotoJ., JahanI., et al.. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer, 2008, 98(4): 845-851

[5] AstinJ.W., BatsonJ., KadirS., et al.. Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat Cell Biol, 2010, 12(12): 1194-1204

[6] NakadaM., NiskaJ.A., TranN.L., et al.. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol, 2005, 167(2): 565-576

[7] TestaJ.R., BellacosaA.. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA, 2001, 98(20): 10983-10985

[8] SpannuthW.A., MangalaL.S., StoneR.L., et al.. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther, 2010, 9(8): 2377-2388

[9] LafleurK., HuangD., ZhouT., et al.. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem, 2009, 52(20): 6433-6446

[10] DopesoH., Mateo-LozanoS., MazzoliniR., et al.. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res, 2009, 69(18): 7430-7438

[11] PennisiA., LingW., LiX., et al.. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood, 2009, 114(9): 1803-1812

[12] WuQ., SuoZ., KristensenG.B., et al.. The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol, 2006, 102(1): 15-21

[13] XiaG., KumarS.R., SteinJ.P., et al.. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene, 2006, 25(5): 769-780

[14] SteinleJ.J., MeiningerC.J., ForoughR., et al.. Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem, 2002, 277(46): 43830-43835

[15] YuanZ.Q., SunM., FeldmanR.I., et al.. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene, 2000, 19(19): 2324-2330

[16] HersI., VincentE.E., TavaréJ.M.. Akt signalling in health and disease. Cell Signal, 2011, 23(10): 1515-1527

[17] ChengJ.Q., GodwinA.K., BellacosaA., et al.. AKT2, a putative oncogene encoding a member of a subfamily of proteinserine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA, 1992, 89(19): 9267-9271

[18] Radeff-HuangJ., SeasholtzT.M., ChangJ.W., et al.. TNF-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent AKT activation and cyclin D expression. J Biol Chem, 2007, 282(2): 863-870

[19] HuddlesonJ.P., AhmadN., SrinivasanS., et al.. Induction of KLF2 by fluid shear stress requires a novel promoter element activated by a phosphatidylinositol 3-kinase-dependent chromatin-remodeling pathway. J Biol Chem, 2005, 280(24): 23371-23379

[20] TongQ., ZhengL., LinL., et al.. Participation of the PI-3K/Akt-NF-kappaB signaling pathways in hypoxia-induced mitogenic factor-stimulated Flk-1 expression in endothelial cells. Respir Res, 2006, 27: 101

[21] WuC., HuangJ.. PI3 kinase-AKT-mTOR pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem, 2007, 282(6): 3571-3583

[22] ChenY., RodrikV., FosterD.A.. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene, 2005, 24(4): 672-679

[23] GaoN., FlynnD.C., ZhangZ., et al.. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol, 2004, 287(2): 281-291

[24] BeeversC.S., LiF., LiuL., et al.. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer, 2006, 119(4): 757-764

[25] WanX., HarkavyB., ShenN., et al.. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene, 2007, 26(13): 1932-1940

[26] MaX., WangS., ZhouJ., et al.. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep, 2005, 14(1): 275-279

[27] ShegogueD., TrojanowskaM.. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem, 2004, 279(22): 23166-23175

[28] LehmannM.J., PatzelV., SczakielG.. Theoretical design of antisense genes with statistically increased efficacy. Nucleic Acids Res, 2000, 28(13): 2597-2604

[29] KoulD., ShenR., BerghS., et al.. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther, 2006, 5(3): 637-644